1887

Abstract

The Middle East respiratory syndrome coronavirus (MERS-CoV) presents a novel emerging threat to public health worldwide. Several treatments for infected individuals have been suggested including IFN, ribavirin and passive immunotherapy with convalescent plasma. Administration of IFN-α2b and ribavirin has improved outcomes of MERS-CoV infection in rhesus macaques when administered within 8 h post-challenge. However, detailed and systematic evidence on the activity of other clinically available drugs is limited. Here we compared the susceptibility of MERS-CoV with different IFN products (IFN-α2b, IFN-γ, IFN-universal, IFN-α2a and IFN-β), as well as with two antivirals, ribavirin and mycophenolic acid (MPA), against MERS-CoV (Hu/Jordan-N3/2012) . Of all the IFNs tested, IFN-β showed the strongst inhibition of MERS-CoV , with an IC of 1.37 U ml, 41 times lower than the previously reported IC (56.08 U ml) of IFN-α2b. IFN-β inhibition was confirmed in the virus yield reduction assay, with an IC of 38.8 U ml. Ribavirin did not inhibit viral replication at a dose that would be applicable to current treatment protocols in humans. In contrast, MPA showed strong inhibition, with an IC of 2.87 µM. This drug has not been previously tested against MERS-CoV and may provide an alternative to ribavirin for treatment of MERS-CoV. In conclusion, IFN-β, MPA or a combination of the two may be beneficial in the treatment of MERS-CoV or as a post-exposure intervention in high-risk patients with known exposures to MERS-CoV.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.061911-0
2014-03-01
2019-11-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/95/3/571.html?itemId=/content/journal/jgv/10.1099/vir.0.061911-0&mimeType=html&fmt=ahah

References

  1. Barnard D. L. , Day C. W. , Bailey K. , Heiner M. , Montgomery R. , Lauridsen L. , Winslow S. , Hoopes J. , Li J. K. . & other authors ( 2006; ). Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. . Antiviral Res 71:, 53–63. [CrossRef] [PubMed]
    [Google Scholar]
  2. Brown C. , Carson G. , Chand M. , Zambon M. . for Public Health England and International Severe Acute Respiratory & Emerging Infection Consortium ( 2013; ). Treatment of MERS-CoV: decision support tool. Clinical decision making tool for the treatment of MERS-CoV v.1.1, 29 July 2013. . Available at: http://isaric.tghn.org/site_media/media/articles/Decision_Support_Document_v1_1_20130729.pdf. Accessed 5 October 2013.
  3. Chan J. F. , Chan K. H. , Kao R. Y. , To K. K. , Zheng B. J. , Li C. P. , Li P. T. , Dai J. , Mok F. K. . & other authors ( 2013a; ). Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. . J Infect 67:, 606–616. [CrossRef] [PubMed]
    [Google Scholar]
  4. Chan R. W. , Chan M. C. , Agnihothram S. , Chan L. L. , Kuok D. I. , Fong J. H. , Guan Y. , Poon L. L. , Baric R. S. . & other authors ( 2013b; ). Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. . J Virol 87:, 6604–6614. [CrossRef] [PubMed]
    [Google Scholar]
  5. de Groot R. J. , Baker S. C. , Baric R. S. , Brown C. S. , Drosten C. , Enjuanes L. , Fouchier R. A. , Galiano M. , Gorbalenya A. E. . & other authors ( 2013; ). Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. . J Virol 87:, 7790–7792. [CrossRef] [PubMed]
    [Google Scholar]
  6. de Wilde A. H. , Raj V. S. , Oudshoorn D. , Bestebroer T. M. , van Nieuwkoop S. , Limpens R. W. , Posthuma C. C. , van der Meer Y. , Bárcena M. . & other authors ( 2013; ). MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. . J Gen Virol 94:, 1749–1760. [CrossRef] [PubMed]
    [Google Scholar]
  7. Falzarano D. , de Wit E. , Martellaro C. , Callison J. , Munster V. J. , Feldmann H. . ( 2013a; ). Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. . Sci Rep 3:, 1686.[PubMed] [CrossRef]
    [Google Scholar]
  8. Falzarano D. , de Wit E. , Rasmussen A. L. , Feldmann F. , Okumura A. , Scott D. P. , Brining D. , Bushmaker T. , Martellaro C. . & other authors ( 2013b; ). Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. . Nat Med 19:, 1313–1317. [CrossRef] [PubMed]
    [Google Scholar]
  9. Henry S. D. , Metselaar H. J. , Lonsdale R. C. , Kok A. , Haagmans B. L. , Tilanus H. W. , van der Laan L. J. . ( 2006; ). Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-α. . Gastroenterology 131:, 1452–1462. [CrossRef] [PubMed]
    [Google Scholar]
  10. ISARIC ( 2013; ). Clinical Decision Making Tool for Treatment of MERS-CoV v.1.1 (29 July). . International Severe Acute Respiratory & Emerging Infection Consortium (ISARIC). Available at: http://isaric.tghn.org/articles/pheisaric-decision-support-document/ Accessed August 5, 2013.
  11. Josset L. , Textoris J. , Loriod B. , Ferraris O. , Moules V. , Lina B. , N’guyen C. , Diaz J. J. , Rosa-Calatrava M. . ( 2010; ). Gene expression signature-based screening identifies new broadly effective influenza A antivirals. . PLoS ONE 5:, e13169. [CrossRef] [PubMed]
    [Google Scholar]
  12. Khan M. , Dhanwani R. , Patro I. K. , Rao P. V. , Parida M. M. . ( 2011; ). Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. . Antiviral Res 89:, 1–8. [CrossRef] [PubMed]
    [Google Scholar]
  13. Kindler E. , Jónsdóttir H. R. , Muth D. , Hamming O. J. , Hartmann R. , Rodriguez R. , Geffers R. , Fouchier R. A. , Drosten C. . & other authors ( 2013; ). Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential. . mBio 4:, e00611. [CrossRef] [PubMed]
    [Google Scholar]
  14. Leyssen P. , Balzarini J. , De Clercq E. , Neyts J. . ( 2005; ). The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. . J Virol 79:, 1943–1947. [CrossRef] [PubMed]
    [Google Scholar]
  15. Ludwig S. . ( 2011; ). Disruption of virus–host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections. . Biol Chem 392:, 837–847.[PubMed] [CrossRef]
    [Google Scholar]
  16. Morrey J. D. , Smee D. F. , Sidwell R. W. , Tseng C. . ( 2002; ). Identification of active antiviral compounds against a New York isolate of West Nile virus. . Antiviral Res 55:, 107–116. [CrossRef] [PubMed]
    [Google Scholar]
  17. Pan Q. , de Ruiter P. E. , Metselaar H. J. , Kwekkeboom J. , de Jonge J. , Tilanus H. W. , Janssen H. L. , van der Laan L. J. . ( 2012; ). Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C virus infection in vitro and in vivo. . Hepatology 55:, 1673–1683. [CrossRef] [PubMed]
    [Google Scholar]
  18. Reed L. J. , Muench H. . ( 1938; ). A simple method of estimating fifty per cent endpoints. . Am J Epidemiol 27:, 493–497.
    [Google Scholar]
  19. Smee D. F. , Bray M. , Huggins J. W. . ( 2001; ). Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. . Antivir Chem Chemother 12:, 327–335.[PubMed] [CrossRef]
    [Google Scholar]
  20. Tisoncik J. R. , Simmons C. P. , Farrar J. , Martin T. R. , Katze M. G. . ( 2012; ). Into the eye of the cytokine storm. . Microbiol Mol Biol Rev 76:, 16–32. [CrossRef] [PubMed]
    [Google Scholar]
  21. World Health Organization ( 2013; ). Global Alert and Response (GAR). Middle East respiratory syndrome coronavirus (MERS-CoV) – update. . Available: http://www.who.int/csr/don/2013_09_20/en/. Accessed 5 October 2013.
  22. Zaki A. M. , Van Boheemen S. , Bestebroer T. M. , Osterhaus A. D. M. E. , Fouchier R. A. M. . ( 2012; ). Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. . N Engl J Med 367:, 1814–1820. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.061911-0
Loading
/content/journal/jgv/10.1099/vir.0.061911-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error